New Investment from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker
Press Releases

New Investment from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker

The DxA partners with Dr's Henrik Zetterberg and Nicholas Ashton to create critical standardized reference materials for leading Alzheimer's blood biomarker, p-Tau217, to ensure consistency across global research and clinical

avatar profile Olean Times Herald

Olean Times Herald


Local & Social